# Effect of Dapagliflozin Administration on the Apoptosis Levels of Patients With Acute Myocardial Infarction

> **NCT06615674** · PHASE4 · COMPLETED · sponsor: **Yoga Yudhistira** · enrollment: 40 (actual)

## Conditions studied

- Acute Myocardial Infarction (AMI)
- STEMI - ST Elevation Myocardial Infarction (MI)
- NSTEMI - Non-ST Segment Elevation Myocardial Infarction (MI)

## Interventions

- **DRUG:** Forxiga® 10 mg Film-Coated Tablet, manufactured by AstraZeneca Pharmaceuticals LP, USA for AstraZeneca Pharmaceuticals Co. Ltd., China imported by PT AstraZeneca Indonesia, Indonesia

## Key facts

- **NCT ID:** NCT06615674
- **Lead sponsor:** Yoga Yudhistira
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2024-09-21
- **Primary completion:** 2024-11-30
- **Final completion:** 2024-12-07
- **Target enrollment:** 40 (ACTUAL)
- **Last updated:** 2025-02-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06615674

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06615674, "Effect of Dapagliflozin Administration on the Apoptosis Levels of Patients With Acute Myocardial Infarction". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06615674. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*